covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Soporte nutricional basado en la evidencia en la enfermedad inflamatoria intesti...
Información de la revista
Vol. 52. Núm. S1.
Nutrición basada en la evidencia
Páginas 70-77 (mayo 2005)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 52. Núm. S1.
Nutrición basada en la evidencia
Páginas 70-77 (mayo 2005)
Nutrición basada en la evidencia
Acceso a texto completo
Soporte nutricional basado en la evidencia en la enfermedad inflamatoria intestinal
Visitas
4505
M.C. Cuerda Compés
Autor para correspondencia
mcuerda.hgugm@salud.madrid.org

Correspondencia: Dra. M.C. Cuerda Compés. Unidad de Nutrición Clínica y Dietética. Hospital General Universitario Gregorio Marañón. Doctor Esquerdo, 46. 28007 Madrid. España.
, I. Bretón Lesmes, M. Camblor Álvarez, P. García Peris
Unidad de Nutrición Clínica y Dietética. Hospital General Universitario Gregorio Marañón. Madrid. España
Este artículo ha recibido
Información del artículo

Los pacientes con enfermedad inflamatoria intestinal se encuentran en riesgo de desnutrición, por lo que debería realizarse un cribado nutricional en todos ellos para identificar a los enfermos que requerirán una valoración nutricional formal. En los pacientes en los que esté indicado iniciar un soporte nutricional debería utilizarse la nutrición enteral (por vía oral o por sonda). No existen diferencias significativas entre las dietas enterales elementales y no elementales para inducir la remisión en pacientes con enfermedad de Crohn. No obstante, dada la mejor tolerancia de estas últimas, las dietas poliméricas son preferidas por la mayoría de autores. La nutrición enteral no debería utilizarse como tratamiento primario de elección en los pacientes con enfermedad de Crohn, ya que induce un número de remisiones inferior al tratamiento esteroideo. Aunque se ha especulado que la grasa de la dieta (cantidad y tipo de grasa) podría tener influencia en la evolución de la enfermedad, los estudios de que disponemos son insuficientes para hacer recomendaciones a este respecto. Tampoco existe evidencia en la actualidad de que la glutamina sea eficaz para inducir la remisión en la enfermedad de Crohn. La utilización de probióticos presenta un alto nivel de evidencia en el tratamiento de mantenimiento y en la prevención de la pouchitis postoperatoria, aunque menor en la colitis ulcerosa y la enfermedad de Crohn. Se necesitan más estudios para investigar algunos problemas, como la dosis, la duración del tratamiento, la utilización por separado o asociando varias cepas, así como el uso concomitante de prebióticos, simbióticos o antibióticos.

Palabras clave:
Enfermedad inflamatoria intestinal
Enfermedad de Crohn
Colitis ulcerosa
Malnutrición
Nutrición enteral
Nutrición parenteral
Glutamina
Prebióticos
Probióticos
Abstract

Patients with inflammatory bowel disease are at risk for malnutrition. Consequently all patients with inflammatory bowel disease should undergo nutritional screening to identify those who require thorough nutritional evaluation. When nutritional support is indicated, enteral nutrition (oral or through a tube) should be used. There are no significant differences between elemental and non-elemental enteral diets in inducing remission of Crohn's disease (CD). Nevertheless, given that non-elemental diets are better tolerated, most authors prefer polymeric diets. Enteral nutrition should not be used as the primary treatment of choice in patients with CD, since they are less effective in inducing remission than steroid therapy. Although dietary fat (quantity and type of fat) might influence the course of the disease, recommendations cannot be made on the basis of the available studies. Equally, there is insufficient evidence that glutamine is effective in inducing remission in CD. The use of probiotics presents a high level of evidence in maintenance treatment and in the prevention of postoperative pouchitis, although the level of evidence is lower in ulcerative colitis and CD. Further studies are required to investigate several issues such as dose, treatment duration, the separate or combined use of several strains, as well as the concomitant use of prebiotics, symbiotics or antibiotics.

Key words:
Inflammatory bowel disease
Crohn's disease
Ulcerative colitis
Malnutrition
Enteral nutrition
Parenteral nutrition
Glutamine
Prebiotics
Probiotics
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Brullet, X. Bonfill, G. Urrutia, V. Ruiz Ochoa, M. Cueto, J. Clofent, et al.
Estudio epidemiológico de la incidencia de enfermedad inflamatoria intestinal en 4 áreas de España.
Med Clin (Barc), 17 (1998), pp. 651-656
[2.]
P. García Peris, C. Cuerda, M. Camblor, I. Bretón.
Nutrición enteral y enfermedades digestivas: enfermedad inflamatoria intestinal.
Endocrinología, 44 (1997), pp. 42-46
[3.]
D.G. Nelly, C.R. Fleming.
Nutricional considerations in inflammatory bowel diseases.
Gastroenterol Clin North Am, 24 (1995), pp. 597-611
[4.]
F. Fernández-Bañares, M.A. Gassull.
Revisión y consenso en terapia nutricional: nutrición en enfermedad inflamatoria intestinal.
Nutr Hosp, 14 (1999), pp. 71-80
[5.]
ASPEN.
Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients.
JPEN, 26 (2002), pp. SA73-SA74
[6.]
ASPEN Board of Directors.
Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients.
JPEN, 17 (1993), pp. 21S-22S
[7.]
H. Lochs, S. Meryn, L. Marosi, P. Ferenci, H. Hortnag.
Has total bowel rest a beneficial effect in treatment of Crohn's disease?.
Clin Nutr, 2 (1983), pp. 61-64
[8.]
G.R. Greenberg, C.R. Fleming, K.N. Jeejeebhoy, I.H. Rosenberger, D. Sales, W.J. Tremaine.
Controlled trial of bowel rest and nutrition support in the management of Crohn's disease.
Gut, 29 (1988), pp. 1309-1315
[9.]
R.J. Dickinson, M.G. Ashton, A.T.R. Axon, R.C. Smith, C.K. Yeung, G.L. Hill.
Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunt to the routine therapy of acute colitis.
Gastroenterology, 79 (1980), pp. 1199-1204
[10.]
P.B. McIntyre, J. Powell-Tuck, S.R. Wood, J.E. Lennard-Jones, E. Lerebours, P. Hecketsweiler, et al.
Controlled trial of bowel rest in the treatment of severe acute colitis.
Gut, 27 (1986), pp. 481-485
[11.]
F. González-Huix, F. Fernández-Bañares, M. Esteve-Comas, A. Abad-Lacruz, E. Cabré, D. Acero, et al.
Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis.
Am J Gastroenterol, 88 (1993), pp. 227-232
[12.]
M.H. Giaffer, G. North, C.D. Holdsworth.
Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease.
Lancet, 335 (1990), pp. 816-819
[13.]
D. Rigaud, J. Cosnes, Y. Le Quintrec, E. Rene, J.P. Gendre, M. Mignon.
Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental vs polimeric diet.
Gut, 32 (1991), pp. 1492-1497
[14.]
R.H.R. Park, A. Galloway, B.J.Z. Danesh, R.I. Russell.
Double-blind controlled trial of elemental and polymeric diets as primary therapy in active Crohn's disease.
Eur J Gastroenterol Hepatol, 3 (1991), pp. 483-490
[15.]
A.H. Raouf, V. Hildrey, J. Daniel, R.J. Walker, N. Krasner, E. Elias, et al.
Enteral feeding as sole treatment for Crohn's disease: Controlled trial of whole protein vs amino acid based feed and a case study of dietary challenge.
Gut, 32 (1991), pp. 702-707
[16.]
S.J. Middleton, A.M. Riordan, J.O. Hunter.
Comparison of elemental and peptide-based diets in the treatment of acute Crohn's disease.
Ital J Gastroenterol, 23 (1991), pp. 609
[17.]
J.C. Mansfield, M.H. Giaffer, C.D. Holdsworth.
Amino-acid versus oligopeptide based enteral feeds in active Crohn's disease.
Gut, 33 (1992), pp. 3S
[18.]
D. Royall, K.N. Jeejeebhoy, J.P. Baker, J.P. Allard, F.M. Habal, S.C. Cunnane, et al.
Comparison of amino acid vs peptide based enteral diets in active Crohn's disease: Clinical and nutritional outcomes.
Gut, 35 (1994), pp. 783-787
[19.]
K. Kobayashi, T. Katsumata, K. Yokohama, H. Takahashi, M. Igarashi, K. Saigenji.
A randomized controlled study of total parenteral nutrition and enteral nutrition by elemental and polymeric diet as primary therapy in active phase of Crohn's disease.
Japanese J Gastroenterol, 95 (1998), pp. 1212-1221
[20.]
S. Verma, S. Brown, B. Kirkwood, M.H. Giaffer.
Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial.
Am J Gastroenterol, 95 (2000), pp. 735-739
[21.]
A.M. Griffiths, F. Pendley, R. Issenman, D. Cockram, K. Jacobsen, M.J. Kelley, et al.
Elemental vs polymeric nutrition as primary treatment of active Crohn's disease: a multi-centre pediatric randomized controlled trial.
J Pediatr Gastroenterol Nutr, 31 (2000), pp. 75S
[22.]
F. Fernández-Bañares, E. Cabré, M. Esteve-Comas, M.A. Gassull.
How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials.
JPEN, 19 (1995), pp. 356-362
[23.]
A. Griffiths, A. Ohlsson, P. Sherman, L.R. Sutherland.
Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease.
Gastroenterology, 108 (1995), pp. 1056-1067
[24.]
M. Zachos, M. Tondeur, A.M. Griffiths.
Enteral nutritional therapy for inducing remission of Crohn's disease.
Cochrane Database Syst Rev, 4 (2004),
[25.]
L. Mahajan, L. Oliva, R. Wyllie, V. Fazio, R. Steffen, M. Kay.
The safety of gastrostomy in patients with Crohn's disease.
Am J Gastroenterol, 92 (1997), pp. 985-988
[26.]
C. O’Morain, A.W. Segal, A.J. Levi.
Elemental diet as primary treatment of acute Crohn's disease: a controlled trial.
BMJ, 288 (1984), pp. 1859-1862
[27.]
E.G. Seidman, L. Bouthillier, A.M. Weber, C.C. Roy, C.L. Morin.
Elemental diet versus prednisone as primary treatment of Crohn's disease.
Gastroenterology, 90 (1986), pp. 1625A
[28.]
E.G. Seidman, M.J. Lohoues, J. Turgeon, L. Bouthillier, C.L. Morin.
Elemental diet versus prednisone as initial therapy in Crohn's disease: early and long-term results.
Gastroenterology, 100 (1991), pp. 150A
[29.]
E.G. Seidman, A.M. Griffiths, A. Jones, R. Issenman, The Canadian Paediatric Crohn's Disease Study Group.
Semi-elemental diet versus prednisone in pediatric Crohn's disease.
Gastroenterology, 104 (1993), pp. 778A
[30.]
I.R. Sanderson, S. Udeen, P.S.W. Davies, M.O. Savage, J.A. Walker-Smith.
Remission induced by elemental diet in small bowel Crohn's disease.
Arch Dis Child, 61 (1987), pp. 123-127
[31.]
H. Malchow, H.J. Steinhardt, H. Lorenz-Meyer, W.D. Strohm, S. Rasmussen, H. Sommer, et al.
Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III.
Scand J Gastroenterol, 25 (1990), pp. 235-244
[32.]
H. Lochs, H.J. Steinhardt, B. Klaus-Wentz, M. Zeitz, H. Vogelsang, H. Sommer, et al.
Comparison of enteral nutrition and drug treatment in active Crohn's disease.
Gastroenterology, 101 (1991), pp. 881-888
[33.]
K.D. Lindor, C.R. Fleming, J.U. Burnes, J.K. Nelson, D.M. Ilstrup.
A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease.
Mayo Clin Proc, 67 (1992), pp. 328-333
[34.]
F. González-Huix, R. De León, F. Fernández-Bañares, M. Esteve, E. Cabré, D. Acero, et al.
Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial.
Gut, 34 (1993), pp. 778-782
[35.]
D.A. Gorard, J.B. Hunt, J.J. Payne-James, K.R. Palmer, R.G.P. Rees, M.L. Clark, et al.
Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone.
Gut, 34 (1993), pp. 1198-1202
[36.]
G.J. Mantzaris, E. Archavlis, P. Amperiadis, D. Kourtessas, G. Triantafyllou.
A randomized prospective trial in active Crohn's disease comparing a polymeric diet, prednisolone and a polymeric diet plus prednisolones.
Gastroenterology, 110 (1996), pp. 955A
[37.]
S. Saverymuttu, H.J.F. Hodgson, V.S. Chadwick.
Controlled trial comparing prednisone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease.
Gut, 26 (1985), pp. 994-998
[38.]
A. Messori, G. Trallori, G. D’Albasio, M. Milla, G. Vannozzi, F. Pacini.
Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis.
Scand J Gastroenterol, 31 (1996), pp. 267-272
[39.]
F. Fernández-Bañares, E. Cabré, F. González-Huix, M.A. Gassull.
Enteral nutrition as primary therapy in Crohn's disease.
Gut, 25 (1994), pp. 55S-59S
[40.]
D.A. Gorard.
Enteral nutrition in Crohn's disease: fat in the formula.
Eur J Gastroenterol Hepatol, 15 (2003), pp. 115-118
[41.]
S.J. Middleton, J.T. Rucker, G.A. Kirby, A.M. Riordan, J.O. Hunter.
Longchain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease.
Clin Nutr, 14 (1995), pp. 229-236
[42.]
T. Bamba, T. Shimoyama, M. Sasaki, T. Tsujikawa, Y. Fukuda, K. Koganei, et al.
Dietary fat attenuates the beneficts of an elemental diet in active Crohn's disease: a randomized, controlled trial.
Eur J Gastroenterol Hepatol, 15 (2003), pp. 151-157
[43.]
K. Leiper, J. Woolner, M.M. Mullan, T. Parker, M. Van der Vliet, S. Fear, et al.
A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease.
Gut, 49 (2001), pp. 790-794
[44.]
V. Khoshoo, R. Reifen, M.G. Neuman, A. Griffiths, P.B. Pencharz.
Effect of low- and high-fat, peptide-based diets on body composition and disease activity in adolescents with active Crohn's disease.
JPEN, 20 (1996), pp. 401-405
[45.]
T. Sakurai, T. Matsui, T. Yao, Y. Takagi, F. Hirai, K. Aoyagi, et al.
Shortterm efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized controlled trial comparing nutrient formulas.
JPEN, 26 (2002), pp. 98-103
[46.]
M.A. Gassull, F. Fernández-Bañares, E. Cabré, M. Papo, M.H. Giaffer, J.L. Sánchez-Lombraña.
Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a doubled blind randomised multicentre European trial.
Gut, 51 (2002), pp. 164-168
[47.]
A. Belluzzi, S. Boschi, C. Brignola, A. Munarini, G. Cariani, F. Miglio.
Polyunsaturated fatty acids and inflammatory bowel disease.
Am J Clin Nutr, 71 (2000), pp. 339S-342S
[48.]
A. Belluzzi, C. Brignola, M. Campieri, A. Pera, S. Boschi, M. Miglioli.
Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease.
N Engl J Med, 334 (1996), pp. 1557-1560
[49.]
H. Lorenz-Meyer, P. Bauer, C. Nicolay, et al.
Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group members (German Crohn's Disease Study group).
Scand J Gastroenterol, 31 (1996), pp. 778-785
[50.]
R. Lorenz, P.C. Weber, P. Szimnau, W. Heldwein, T. Strasser, K. Loeschke.
Supplementation with ω-3 fatty acids from fish oil in chronic inflammatory bowel disease; a randomised, placebo-controlled, double-blind cross-over trial.
J Intern Med, 225 (1989), pp. 225-232
[51.]
C. O’Morain, A. Tobin, T. McColl, et al.
Fish oil in the treatment of ulcerative colitis.
J Gastroenterol, 4 (1990), pp. 420-423
[52.]
W.F. Stenson, D. Cort, J. Rodgers, et al.
Dietary supplementation with fish oil in ulcerative colitis.
Ann Intern Med, 116 (1992), pp. 609-614
[53.]
A.B. Hawthorne, T.K. Daneshmend, C.J. Hawkey, et al.
Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial.
Gut, 33 (1992), pp. 922-928
[54.]
A. Aslan, G. Triadafilopoulos.
Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, cross-over study.
Am J Gastroenterol, 87 (1992), pp. 432-437
[55.]
K. Loeschke, B. Uebewrschaer, A. Pietsch, et al.
ω-3 Fatty acids retard early relapse in ulcerative colitis in remission.
Dig Dis Sci, 41 (1996), pp. 2087-2094
[56.]
S.M. Greenfield, A.T. Green, J.P. Teare, et al.
A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis.
Aliment Pharmacol Ther, 7 (1993), pp. 159-166
[57.]
I. Dichi, P. Frenhane, J.B. Dichi, et al.
Comparison of ω3 fatty acids and sulfasalazine in ulcerative colitis.
Nutrition, 16 (2000), pp. 87-90
[58.]
R.R. Van der Hulst, B.K. Van Kreel, M.F. Von Meyenfeldt, et al.
Glutamine and the preservation of gut integrity.
Lancet, 341 (1993), pp. 1363-1365
[59.]
E. Den Hond, M. Hiele, M. Peeters, Y. Ghoos, P. Rutgeerts.
Effect of long-term oral glutamine supplements on small intestine permeability in patients with Crohn's disease.
JPEN, 23 (1999), pp. 7-11
[60.]
A.K. Akobeng, V. Miller, J. Stanton, A.M. Elbadri, A.G. Thomas.
Doubleblind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease.
J Pediatr Gastroenterol Nutr, 30 (2000), pp. 78-84
[61.]
N. Delzenne, C. Cherbut, A. Neyrinck.
Prebiotics: actual and potential effects in inflammatory and malignant colonic diseases.
Curr Opin Clin Metab Care, 6 (2003), pp. 581-586
[62.]
A. Swindsindki, A. Ladhoff, A. Pernthaler, S. Swindsinski, V. Loening-Baucke, M. Ortner.
Mucosal flora in inflammatory bowel disease.
Gastroenterology, 122 (2002), pp. 44-54
[63.]
M.A. Chapman, M.F. Grahn, M.A. Boyle, et al.
Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis.
Gut, 35 (1994), pp. 73-76
[64.]
Y. Kim.
Short-chain fatty acids in ulcerative colitis.
Nutr Rev, 56 (1998), pp. 17-24
[65.]
F. Fernández-Bañares, J. Hinojosa, J.L. Sánchez-Lombraña, E. Navarro, J.F. Martínez-Salmerón, A. García-Pugés, et al.
Randomized clinical trial of plantago ovata sedes (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis.
Am J Gastroenterol, 94 (1999), pp. 427-433
[66.]
P. García Peris, C. Cuerda, M. Camblor, I. Bretón, A. Matilla, V. González Lara, et al.
Dieta enteral polimérica estándar vs dieta enteral polimérica con fibra soluble en pacientes con colitis ulcerosa.
Rev Esp Enf Dig, 89 (1997), pp. 86-87
[67.]
C.F.M. Welters, E. Heineman, F.B.J.M. Thunnissen, A.E.J.M. Van den Bogaard, P.B. Soeters, C.G.M.I. Baeten.
Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal puchanal anastomosis.
Dis Colon Rectum, 45 (2002), pp. 621-627
[68.]
O. Kanauchi, T. Suga, M. Tochihara, et al.
Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial.
J Gastroenterol, 37 (2002), pp. 67-72
[69.]
W. Kruis.
Antibiotics and probiotics in inflammatory bowel disease.
Aliment Pharmacol Ther, 20 (2004), pp. 75-78
[70.]
J.H. Kwon, R.J. Farrell.
Probiotics and imflammatory bowel disease.
Biodrugs, 17 (2003), pp. 179-186
[71.]
R.N. Fedorak, K.L. Madsen.
Probiotics and the management of inflammatory bowel disease.
Inflammatory Bowel Diseases, 10 (2004), pp. 286-299
[72.]
W. Kruis, E. Schutz, P. Fric, B. Fixa, G. Judmaier, M. Stolte.
Double-blind comparison of an oral Escherichia coli presentation and mesalazine in mantaining remission of ulcerative colitis.
Aliment Pharmacol Ther, 11 (1997), pp. 853-858
[73.]
W. Kruis, P. Fric, J. Pokrotnieks, M. Lukas, B. Fixa, M. Kascak, et al.
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazina.
Gut, 53 (2004), pp. 1617-1623
[74.]
B.J. Rembacken, A.M. Snelling, P.M. Hawkey, D.M. Chalmers, A.T. Axon.
Non-pathogenic Escherichia coli versus mesalazina for the treatment of ulcerative colitis: a randomised trial.
Lancet, 354 (1999), pp. 635-639
[75.]
K. Plein, J. Hotz.
Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea- a pilot study.
Z Gastroenterol, 31 (1993), pp. 129-134
[76.]
M. Guslandi, G. Mezzi, M. Sorghi, P.A. Testoni.
Saccharomyces boulardii in maintenance treatment of Crohn's disease.
Dig Dis Sci, 45 (2000), pp. 1462-1464
[77.]
H.A. Malchow.
Crohn's disease and Escherichia coli. A new a pproachin therapy to maintain remission of colonic Crohn's disease?.
J Clin Gastroenterol, 25 (1997), pp. 653-658
[78.]
M. Campieri, F. Rizzello, A. Venturi, et al.
Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of postoperative recurrence of Crohn's disease: a randomised controlled study versus mesalazine.
Gastroenterology, 118 (2000), pp. 4179
[79.]
P. Gionchetti, F. Rizello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, et al.
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
Gastroenterology, 119 (2000), pp. 305-309
[80.]
T. Mimura, F. Rizzello, U. Helwig, G. Poggioli, S. Schreiber, I.C. Talbot, et al.
Once daily high dose probiotic therapy (VSL-3) for maintaining remission in recurrent or refractory pouchitis.
Gut, 53 (2004), pp. 108-114
[81.]
P. Gionchetti, F. Rizello, U. Helwig, A. Venturi, K.M. Lammaers, P. Brigidi.
Prophylaxis of pouchitis onset with probiotics therapy: a doubleblind placebo-controlled trial.
Gastroenterology, 124 (2003), pp. 1202-1209
[82.]
C. Prantera, M.L. Scribano, G. Falasco, A. Andreoli, C. Luzi.
Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.
Gut, 51 (2002), pp. 405-409
[83.]
A.L. Hart, A.J. Stagg, M.A. Kamm.
Use of probiotics in the treatment of inflammatory bowel disease.
J Clin Gastroenterol, 36 (2003), pp. 111-119
[84.]
V.E. Rolfe, F. Bath-Hextall, P. Fortun, C.J. Hawkey.
Probiotics for the maintenance of remission in Crohn's disease.
Cochrane Database Syst Rev, 4 (2004),
[85.]
W. Sandborn, R. McLeod, D. Jewell.
Pharmacotherapy for induction and maintenance of remission in pouchitis.
Cochrane Database Syst Rev, 4 (2004),
Copyright © 2005. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos